Figure 3From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study Kaplan-Meier curves for (A) overall survival, (B) time to progression. The blue line corresponds to group A, while the red line to group B.Back to article page